Triple negative breast cancer (TNBC) & Other Solid tumors
|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||Commercial Rights|
|eryaspase (GRASPA® (1))||Asparaginase||TNBC 1L|
Following the positive clinical data in pancreatic cancer, ERYTECH intends to develop eryaspase for the treatment of triple negative breast cancer and selected other solid tumor indications. We are investigating the possibility to conduct clinical trials in one or more Non-Hodgkin Lymphoma (NHL) indications.